-
Something wrong with this record ?
Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients
J. Halamkova, I. Kiss, Z. Pavlovsky, J. Tomasek, J. Jarkovsky, Z. Cech, S. Tucek, L. Hanakova, M. Moulis, J. Zavrelova, M. Man, P. Benda, O. Robek, Z. Kala, M. Penka,
Language English Country Slovakia
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Adenocarcinoma metabolism secondary therapy MeSH
- Urokinase-Type Plasminogen Activator metabolism MeSH
- Adult MeSH
- Immunoenzyme Techniques MeSH
- Plasminogen Activator Inhibitor 1 metabolism MeSH
- Plasminogen Activator Inhibitor 2 metabolism MeSH
- Colectomy MeSH
- Colorectal Neoplasms metabolism pathology therapy MeSH
- Combined Modality Therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Survival Rate MeSH
- Prospective Studies MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Receptors, Urokinase Plasminogen Activator metabolism MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Urokinase (uPA) plays an essential role in the activation of plasminogen to plasmin, and together with its receptor (uPAR), tissue activator (tPA) and urokinase inhibitors (PAI 1, PAI 2, PAI 3 and protease nexin) forms the plasminogen activator system (PAS), a component of metastatic cascade importantly contributing to the invasive growth and angiogenesis of malignant tumours. In our project we examined the expression of uPA, uPAR, PAI 1 and PAI 2 in tumor tissue and we also studied the plasma levels of PAI 1 before and after the initiation of therapy in patients with colorectal carcinoma in relationship to grade of tumor and the treatment response. In our prospective evaluation we included 80 patients treated for adenocarcinoma of the colon and rectum. Analysis of collected data revealed statistically significant evidence of a relationship between the level of PAI 1 in plasma before treatment and grade of the tumor, which increases with tumor grade (p=0.025). We demonstrated that there exists a statistically significant relationship between the expression of PAI 2 (p<0.001) and uPAR (p=0.031) and grade of tumor. We also confirmed a statistically significant relationship between soluble levels of PAI 1 before treatment and therapeutic response (p=0.021). In our group of patients the expression of uPA, uPAR, PAI 1 and 2 in tumor tissue in relation to response to treatment was also assessed. Our results suggest that the greater expression of these parameters in tumor tissue is linked to a worse response to therapy. In conclusion, PAS factors help as a prognostic indicators and could also act as a predictive factor in colorectal carcinoma.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12027474
- 003
- CZ-PrNML
- 005
- 20200429134704.0
- 007
- ta
- 008
- 120817s2011 xo f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.4149/neo_2011_05_377 $2 doi
- 035 __
- $a (PubMed)21744990
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xo
- 100 1_
- $a Halámková, Jana $7 xx0121826 $u Masaryk Memorial Cancer Institute, Faculty of Medicine Masaryk University Brno Zluty kopec, Brno, Czech Republic.
- 245 10
- $a Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients / $c J. Halamkova, I. Kiss, Z. Pavlovsky, J. Tomasek, J. Jarkovsky, Z. Cech, S. Tucek, L. Hanakova, M. Moulis, J. Zavrelova, M. Man, P. Benda, O. Robek, Z. Kala, M. Penka,
- 520 9_
- $a Urokinase (uPA) plays an essential role in the activation of plasminogen to plasmin, and together with its receptor (uPAR), tissue activator (tPA) and urokinase inhibitors (PAI 1, PAI 2, PAI 3 and protease nexin) forms the plasminogen activator system (PAS), a component of metastatic cascade importantly contributing to the invasive growth and angiogenesis of malignant tumours. In our project we examined the expression of uPA, uPAR, PAI 1 and PAI 2 in tumor tissue and we also studied the plasma levels of PAI 1 before and after the initiation of therapy in patients with colorectal carcinoma in relationship to grade of tumor and the treatment response. In our prospective evaluation we included 80 patients treated for adenocarcinoma of the colon and rectum. Analysis of collected data revealed statistically significant evidence of a relationship between the level of PAI 1 in plasma before treatment and grade of the tumor, which increases with tumor grade (p=0.025). We demonstrated that there exists a statistically significant relationship between the expression of PAI 2 (p<0.001) and uPAR (p=0.031) and grade of tumor. We also confirmed a statistically significant relationship between soluble levels of PAI 1 before treatment and therapeutic response (p=0.021). In our group of patients the expression of uPA, uPAR, PAI 1 and 2 in tumor tissue in relation to response to treatment was also assessed. Our results suggest that the greater expression of these parameters in tumor tissue is linked to a worse response to therapy. In conclusion, PAS factors help as a prognostic indicators and could also act as a predictive factor in colorectal carcinoma.
- 650 _2
- $a adenokarcinom $x metabolismus $x sekundární $x terapie $7 D000230
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a kolektomie $7 D003082
- 650 _2
- $a kolorektální nádory $x metabolismus $x patologie $x terapie $7 D015179
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoenzymatické techniky $7 D007124
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a inhibitor aktivátoru plazminogenu 1 $x metabolismus $7 D017395
- 650 _2
- $a inhibitor aktivátoru plazminogenu 2 $x metabolismus $7 D017396
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a receptory urokinázového aktivátoru plazminogenu $x metabolismus $7 D055293
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a aktivátor plasminogenu urokinasového typu $x metabolismus $7 D014568
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kiss, Igor, $d 1965- $7 xx0031864
- 700 1_
- $a Pavlovský, Zdeněk, $d 1971- $7 xx0136659
- 700 1_
- $a Tomasek, J
- 700 1_
- $a Jarkovský, Jiří, $d 1976- $7 stk2008461294
- 700 1_
- $a Čech, Zbyněk $7 xx0126345
- 700 1_
- $a Tucek, S
- 700 1_
- $a Hanakova, L
- 700 1_
- $a Moulis, M
- 700 1_
- $a Zavřelová, Jiřina $7 xx0168330
- 700 1_
- $a Man, M
- 700 1_
- $a Benda, P
- 700 1_
- $a Robek, O
- 700 1_
- $a Kala, Zdeněk, $d 1960- $7 xx0003702
- 700 1_
- $a Penka, M
- 773 0_
- $w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 58, č. 5 (2011), s. 377-85
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21744990 $y Pubmed
- 910 __
- $a ABA008 $b A 1194 $c 659 $y m $z 0
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20200429134659 $b ABA008
- 999 __
- $a ok $b bmc $g 949516 $s 784820
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 58 $c 5 $d 377-85 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
- LZP __
- $a Pubmed-20120817/11/03